SigmaDrugs
Budapest-based biotech start-up (founded 2015) focusing on preclinical development of small-molecule therapeutics that target the Sigma-1 receptor for treatment of organ fibrosis (kidney, lung, eye) and on development of organ preservation solutions to improve transplantation outcomes. The group conducts in vitro and in vivo translational research, files and prosecutes patents, and collaborates with academic partners and international conferences.
Industries
Nr. of Employees
small (1-50)
SigmaDrugs
Products
Organ preservation solution (preclinical)
A formulated preservation solution intended for cold storage of donor organs to protect grafts and improve transplantation outcomes; associated with patent filings.
Sigma-1 receptor agonist therapeutic program (preclinical)
Preclinical therapeutic program focused on sigma-1 receptor agonists for treating organ fibrosis (kidney, lung, ocular) including candidates tested in cell and rodent models.
Organ preservation solution (preclinical)
A formulated preservation solution intended for cold storage of donor organs to protect grafts and improve transplantation outcomes; associated with patent filings.
Sigma-1 receptor agonist therapeutic program (preclinical)
Preclinical therapeutic program focused on sigma-1 receptor agonists for treating organ fibrosis (kidney, lung, ocular) including candidates tested in cell and rodent models.
Services
Preclinical translational research and collaboration
Collaborative execution of in vitro and in vivo studies to evaluate therapeutic candidates and preservation solutions in fibrosis and transplantation research.
Preclinical translational research and collaboration
Collaborative execution of in vitro and in vivo studies to evaluate therapeutic candidates and preservation solutions in fibrosis and transplantation research.
Expertise Areas
- Antifibrotic drug discovery
- Organ preservation and transplantation research
- Preclinical translational research (rodent models)
- Ophthalmic drug development and trabecular meshwork biology
Key Technologies
- Sigma-1 receptor pharmacology
- 3D organoid models
- In vitro cell culture and molecular assays
- Rodent transplantation and ischemia/reperfusion models